# Characterization, Treatment Patterns and Outcomes of Patients Experiencing Severe Toxicity to 5-FU or Capecitabine

<!-- studyStatus: start -->

![Study Status: Started](https://img.shields.io/badge/Study%20Status-Started-blue.svg)

<!-- studyStatus: end -->

[![CDM Version](https://img.shields.io/badge/CDM%20Version-5.4-lemonchiffon.svg)](https://ohdsi.github.io/CommonDataModel/cdm54.html)

[![Vocabulary Version](https://img.shields.io/badge/Vocabulary%20Version-5.0-rosybrown.svg)](https://github.com/OHDSI/Vocabulary-v5.0)

## Project Information

### Meta

-   **Study Lead**: Suzanne Ward
-   **Analytics Use Case**: Characterization
-   **Study Start Date**: 2023-11-01
-   **Study End Date**: 2099-12-31
-   **Study Tags**: TBD
-   **Protocol**: TBD
-   **Publications**: TBD
-   **Results Explorer**: TBD

### Contributors

-   **Star Biopharma Consulting**
    -   Setareh Williams
    -   Monica Bianchini
-   **Odysseus Data Services**
    -   Asieh Golozar
    -   Martin Lavallee
    -   George Argyriou
    -   Lucy McDermott

## Description

This study aims to address what the demographic and clinical characteristics, and outcomes are of patients who are treated with Vistogard and patients with severe 5-FU or capecitabine toxicity or overdose not treated with Vistogard.

## Data

This study will be run on the following OMOP databases:

| Database    | Country | Responsible Party |
|-------------|---------|-------------------|
| Open Claims | USA     | IQVIA             |

## Study Documentation

-   [**How To Run**](https://github.com/OdyOSG/vistogardStudy/blob/main/HowToRun.md)
-   [**Contribution Guidelines**]
